P. falciparum is highly virulent in nature because of its ability to modify the infected host
red blood cells, adherence to the vascular endothelium and changes in antigenicity at different stages.
Also slow migration time in the dermal and endothelial cells leads to decreased immune response. To
overcome the problems, there is a need to design a vaccine which increases the migration time of the
parasite, enhances the immune response, enables recognition of surface antigens and causes minimal
clinical infection as a side-effect. An ITI-based (Infection-Treatment Immunization) vaccine
development strategy is to be adopted to develop this novel vaccine. This will include administration
of a liquid solution of purified, non-attenuated sporozoites from an infected female Anopheles
mosquito, AS02A adjuvant and chlorate (a metabolic inhibitor of sulfation that decreases the extent of
GAG sulfation). To control infection, a drug-cover of artemisinin will be administered as a part of the
vaccination strategy along with a specific protease inhibitor MRT12113 which prevents RBC rupture
and reinvasion by the parasite. This vaccine will intend to increase the overall migration time of the
parasite in blood which is otherwise approximately 30 minutes, resulting in an overall enhanced
immune response. It also intends to reduce parasite invasion in cells and their consequent rupture thus
preventing the clinical condition-malaria.